Michel Detheux

2023

In 2023, Michel Detheux earned a total compensation of $5.8M as Ph.D. Chief Executive Officer at iTeos Therapeutics, a 45% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$384,516
Option Awards$4,428,800
Salary$578,863
Stock Awards$295,200
Other$80,395
Total$5,767,774

Detheux received $4.4M in option awards, accounting for 77% of the total pay in 2023.

Detheux also received $384.5K in non-equity incentive plan, $578.9K in salary, $295.2K in stock awards and $80.4K in other compensation.

Rankings

In 2023, Michel Detheux's compensation ranked 90th out of 2,978 executives tracked by ExecPay. In other words, Detheux earned more than 97.0% of executives.

ClassificationRankingPercentile
All
90
out of 2,978
97th
Division
Manufacturing
48
out of 1,637
97th
Major group
Chemicals And Allied Products
31
out of 906
97th
Industry group
Drugs
30
out of 869
97th
Industry
Biological Products, Except Diagnostic Substances
11
out of 211
95th
Source: SEC filing on April 25, 2024.

Detheux's colleagues

We found two more compensation records of executives who worked with Michel Detheux at iTeos Therapeutics in 2023.

2023

Matthew Call

iTeos Therapeutics

Chief Operating Officer

2023

Matthew Gall

iTeos Therapeutics

Chief Financial Officer

News

In-depth

You may also like